Abstract | INTRODUCTION: AIM: EVIDENCE REVIEW: Available evidence suggests that dronedarone 400 mg orally twice daily can lengthen the time to and decrease the overall recurrence of atrial fibrillation compared with placebo. Dronedarone may reduce risk of mortality and cardiovascular hospitalization. Patients with atrial fibrillation receiving dronedarone had improved ventricular rate control compared with patients receiving placebo. Dronedarone is associated with few serious adverse events except, notably, in patients with decompensated heart failure. PLACE IN THERAPY: CONCLUSION:
|
Authors | Renee M Sullivan, Brian Olshansky |
Journal | Core evidence
(Core Evid)
Vol. 5
Pg. 49-59
(Oct 21 2010)
ISSN: 1555-175X [Electronic] New Zealand |
PMID | 21042542
(Publication Type: Journal Article)
|